Omni Health Inc (OMHE)

[mattsinvestmentclub]

COMMERCIALIZATION WILL BEGIN IN Q3 2023.

Our pipeline is positioned to deliver both near-term and sustained growth in two waves:? In the near-term, the OTC formulation launch through FY2023 will start bringing a steady revenue stream, representing best-in-class or first-in-class therapies. Looking to FY2024 and beyond, our R&D engine with internal research capabilities and external partnerships is expected to deliver a steady stream of next-generation pain therapies that will sustain our growth.